A combination therapy of Ramucirumab and Paclitazel as second-line treatment for elderly gastric cancer patients: A exploratory phase II research
Latest Information Update: 05 Dec 2023
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions
- 01 Dec 2023 Results evaluating the feasibility and efficacy of this regimen for older patients, published in the Anticancer Research.
- 01 Dec 2023 Status changed from not yet recruiting to completed, as per results published in the Anticancer Research.
- 05 Dec 2016 New trial record